Mohammed Kashani-Sabet, M.D., Senior Scientist; Director of CPMC’s Center for Melanoma Research and Treatment

California Pacific CURRENTS: The online journal of CPMC Research Institute

Developing new approaches to the prognostic assessment and treatment of cutaneous malignancies
  • Immunofluorescence analysis of expression of mesechymal-biomarker proteins

    The displayed image exhibits immunofluorescence analysis of expression of the mesechymal-biomarker proteins (vimentin, N-cadherin, and slug), which, in comparison to a control, are significantly decreased following miR-18b overexpression in human melanoma cells.

    MicroRNA-18b (miR-18b) expression is suppressed in a subset of melanomas, and miR-18b acts as a tumor suppressor. Overexpression of miR-18b was identified as a novel strategy to activate p53 expression and suppress melanoma cell growth. miR-18b overexpression also results in suppression in the ability of melanoma cells to migrate and invade, and reverses epithelial-to-mesenchymal transition, which is critical to tumor cell aggressiveness and metastatic potential.

  • Immunofluorescence analysis of expression of mesechymal-biomarker proteins

    The displayed image exhibits immunofluorescence analysis of expression of the mesechymal-biomarker proteins (vimentin, N-cadherin, and slug), which, in comparison to a control, are significantly decreased following miR-18b overexpression in human melanoma cells.

    MicroRNA-18b (miR-18b) expression is suppressed in a subset of melanomas, and miR-18b acts as a tumor suppressor. Overexpression of miR-18b was identified as a novel strategy to activate p53 expression and suppress melanoma cell growth. miR-18b overexpression also results in suppression in the ability of melanoma cells to migrate and invade, and reverses epithelial-to-mesenchymal transition, which is critical to tumor cell aggressiveness and metastatic potential.

+

Research Overview

  • Recent cDNA microarray analyses of moles and primary and metastatic melanomas performed by Dr. Kashani’s laboratory have identified a number of genes whose expression levels can be used to distinguish between known landmarks in the tumor progression cascade of melanoma.
    • The lab has identified novel biomarkers associated with each stage of melanoma progression, and has described a molecular diagnostic assay for melanoma that yields sensitivity, specificity and diagnostic accuracy of greater than 90% in the diagnosis of melanocytic neoplasms.
  • Researchers at CPMCRI have already identified a number of targets implicated in tumor proliferation or invasion; studies are underway in the Kashani lab to assess activation of these targets and their signaling pathways in the context of known molecular subtypes, to identify further enriched targets.
  • Dr. Kashani leads CPMC’s Center for Melanoma Research and Treatment, and he is the primary investigator for a new integrated research program at CPMCRI seeking to develop effective combination therapies for aggressive and metastatic tumors, including melanomas, breast cancers and glioblastomas.
  • Dr. Kashani leads melanoma and biomarker efforts for CPMCRI's Cancer Avatar Project.

Listen to Dr. Kashani's perspectives on cutting-edge melanoma research at CPMC.


Training


Dr. Kashani received his M.D. from SUNY Stony Brook and he was a resident and post-doctoral Fellow in dermatology and oncology at the University of California, San Francisco.


 

Publication Search

Publications

Bezrookove V, Nosrati M, Miller JR, de Semir D, Dar AA, Vosoughi E, Vaquero E, Sucker A, Lazar AJ, Gershenwald JE, Davies MA, Schadendorf D, Kashani-Sabet M, Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma. Clin Cancer Res

Vosoughi E, Lee JM, Miller JR, Nosrati M, Minor DR, Abendroth R, Lee JW, Andrews BT, Leng LZ, Wu M, Leong SP, Kashani-Sabet M, Kim KB, Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies. BMC Cancer

Chang JM, Kosiorek HE, Dueck AC, Leong SPL, Vetto JT, White RL, Avisar E, Sondak VK, Messina JL, Zager JS, Garberoglio C, Kashani-Sabet M, Pockaj BA, Stratifying SLN incidence in intermediate thickness melanoma patients. Am J Surg

Jiang B, Patino MM, Gross AJ, Leong SPL, Moretto JC, Kashani-Sabet M, Kim KB, Diffuse granulomatous panniculitis associated with anti PD-1 antibody therapy. JAAD Case Rep

Faries MB, Mozzillo N, Kashani-Sabet M, Thompson JF, Kelley MC, DeConti RC, Lee JE, Huth JF, Wagner J, Dalgleish A, Pertschuk D, Nardo C, Stern S, Elashoff R, Gammon G, Morton DL, MMAIT-IV Clinical Trial Group., Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases. Ann Surg Oncol

Kashani-Sabet M, Nosrati M, Miller JR 3rd, Sagebiel RW, Leong SPL, Lesniak A, Tong S, Lee SJ, Kirkwood JM, Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690. Clin Cancer Res

VIEW ALL
Mohammed Kashani-Sabet, M.D., Senior Scientist; Director of CPMC’s Center for Melanoma Research and Treatment
Primary Research Interests
  • Development and validation of molecular diagnostic markers for melanoma
  • Development and validation of molecular prognostic and predictive factors for melanoma and other cancers
  • Identification of miRNA markers of melanoma progression
  • Identification of functional mediators of tumor progression and metastasis
  • Identification of markers and mediators of resistance to targeted therapy
  • Identification of novel targets for treating advanced solid tumors
     

Lab Members

Vladimir Bezrookove, Ph.D.
Post-doctoral researcher
Altaf Dar, Ph.D.
Associate Scientist
Sebastien De Feraudy, M.D., Ph.D.
Post-doctoral researcher
David de Semir, Ph.D.
Associate Scientist
Reza Keikhaee, Ph.D.
Visiting Scholar
Jee Min Lee, B.S.
Research Technician
Mehdi Nosrati
Lab Manager
Program Manager of the Cancer Avatar Project

Lab Volunteers

Madeleine Bauer, B.S. (Austria)
Caroline Garger, B.S. (Austria)
Lauren McConnell, B.S. (Ireland)
Binh Phan, B.S.
Sara Ursu, B.S..
Elham Vosoughi, M.D.